482 related articles for article (PubMed ID: 33042263)
1. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
2. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
4. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
5. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM
Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430
[TBL] [Abstract][Full Text] [Related]
6. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.
Xu L; Qu JL; Song N; Zhang LY; Zeng X; Che XF; Hou KZ; Shi S; Feng ZY; Qu XJ; Liu YP; Teng YE
Oncol Rep; 2020 Dec; 44(6):2443-2454. PubMed ID: 33125141
[TBL] [Abstract][Full Text] [Related]
8. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
10. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
11. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA.
Zhang Q; Lei L; Jing D
Oncol Rep; 2020 Nov; 44(5):1875-1884. PubMed ID: 33000256
[TBL] [Abstract][Full Text] [Related]
13. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
14. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
[TBL] [Abstract][Full Text] [Related]
15. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
[TBL] [Abstract][Full Text] [Related]
17. Genomic features of rapid versus late relapse in triple negative breast cancer.
Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
[TBL] [Abstract][Full Text] [Related]
18. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
19. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
